12:32 PM EDT, 09/27/2024 (MT Newswires) -- Estrella Immunopharma ( ESLA ) shares were up 20% in recent Friday trading after the company said a patient receiving its EB103 therapy achieved complete response in an ongoing trial of the medicine.

The patient, the first to be enrolled in the phase 1/2 open-label Starlight-1 trial, was diagnosed with follicular lymphoma. One month after receiving an infusion of EB103 the patient had no detectable signs of disease or cancer remaining, the company said.

The patient had relapsed three times following prior treatments, according to Estrella.

"We are cautiously optimistic about these early results and the favorable safety profile of EB103 observed in our first treated patient of this clinical trial," Estrella Chief Executive Cheng Liu said in a statement.

Price: 1.19, Change: +0.22, Percent Change: +22.69